Three Years in Remission: Does Autoimmune Hepatitis Still Need Its Own Drug
A patient with three years of biochemical remission from autoimmune hepatitis wants to know whether she still needs to take azathioprine. The debate turns out to hinge less on how long she's been in remission than on what kind of remission has actually been documented.
Beatriz M., a 36-year-old woman, works remotely as a graphic designer and has spent the past year training for her first half-marathon, a goal she says she wouldn't have had the energy for during her diagnosis year. She was diagnosed with autoimmune hepatitis five years ago after presenting with fatigue and an ALT in the 400s, treated initially with prednisone and azathioprine and tapered off steroids within the first year. She has been on azathioprine monotherapy since, with normal ALT, normal IgG, and negative ANA titers at every check for the past three years — a genuinely sustained biochemical remission by every standard lab measure her hepatologist tracks. She has no cirrhosis on her most recent imaging and no history of decompensation at any point in her disease course.
What she's actually asking, at this visit, is whether three years is long enough to try coming off azathioprine altogether. The honest answer depends on data that cuts both ways: published relapse rates after withdrawal in autoimmune hepatitis run high — van Gerven's randomized withdrawal trial found relapse in the large majority of patients stopping azathioprine against a small minority continuing it, and observational series put the range at roughly half to four out of five within a few years off therapy, even among patients whose pre-withdrawal remission looked as clean as hers does on paper. Years of continued azathioprine exposure carry their own real, if smaller, cumulative risks — and neither number tells her, individually, which side of that split she'd land on.
What her labs do and don't tell the team
I'd support attempting withdrawal. Three years of clean biochemical remission is a genuinely long track record in this disease, and indefinite azathioprine isn't free — it carries its own real cumulative risk the longer she stays on it. A remission this durable is exactly the population most likely to tolerate coming off therapy successfully.
I manage long-term immunosuppression in a lot of patients whose labs look this clean going into a withdrawal attempt, and the published relapse data in autoimmune hepatitis specifically still concerns me — a meaningful majority of patients relapse within a few years off therapy, even among strong pre-withdrawal responders. Her individual numbers being good doesn't mean she's not part of that majority.
'A long track record' is doing a lot of work in that argument, and duration of biochemical remission hasn't been shown to reliably predict who stays in remission off therapy — it's necessary, by every protocol I've seen, but the data doesn't support treating it as sufficient on its own.
I want to name something underneath both of your positions: her only liver biopsy was two years into treatment, and it showed residual mild inflammatory activity at that point — before three of these four years of normal labs ever happened. Biochemical remission and histologic remission are known to diverge in this disease specifically, which is exactly why most withdrawal protocols require a recent biopsy confirming true histologic quiescence before attempting it, not normal labs alone. I wouldn't move forward on a withdrawal attempt without repeating that biopsy first.
No withdrawal attempted today. Azathioprine continued while a repeat liver biopsy is scheduled to establish whether histologic, not just biochemical, remission has actually been achieved.
Beatriz agreed to the plan once the reasoning was explained directly, though she was candid that the delay was a disappointment; the team documented her preference for withdrawal explicitly, to be revisited as soon as biopsy results return rather than left open-ended.